Evolent Health Inc. (NYSE:EVH) – Equities researchers at Leerink Swann issued their Q2 2017 earnings per share estimates for shares of Evolent Health in a note issued to investors on Sunday. Leerink Swann analyst D. Larsen expects that the firm will post earnings of ($0.11) per share for the quarter. Leerink Swann has a “Buy” rating and a $24.00 price target on the stock. Leerink Swann also issued estimates for Evolent Health’s FY2018 earnings at $0.05 EPS.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. The business had revenue of $60.20 million for the quarter, compared to analyst estimates of $58.35 million. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) earnings per share.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, October 11th. Jefferies Group set a $28.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research note on Tuesday, October 4th. Canaccord Genuity set a $30.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research note on Wednesday, September 28th. FBR & Co upped their price objective on shares of Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a research note on Friday, August 5th. Finally, William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Friday, September 30th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $27.83.

Shares of Evolent Health (NYSE:EVH) traded down 0.363% during mid-day trading on Wednesday, hitting $20.575. 154,462 shares of the stock were exchanged. Evolent Health has a 12-month low of $8.14 and a 12-month high of $26.84. The stock’s 50 day moving average price is $21.49 and its 200-day moving average price is $20.71. The stock’s market capitalization is $1.40 billion.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Evolent Health by 7.7% in the second quarter. Vanguard Group Inc. now owns 1,015,527 shares of the company’s stock worth $19,499,000 after buying an additional 72,454 shares during the last quarter. Systematic Financial Management LP acquired a new position in Evolent Health during the second quarter valued at $3,480,000. Nationwide Fund Advisors increased its position in Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares during the last quarter. JPMorgan Chase & Co. increased its position in Evolent Health by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 1,338,238 shares of the company’s stock valued at $25,694,000 after buying an additional 47,773 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Evolent Health during the second quarter valued at $1,565,000. Institutional investors own 37.14% of the company’s stock.

In related news, COO Thomas Peterson III sold 72,827 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total transaction of $1,568,693.58. Following the transaction, the chief operating officer now owns 377,623 shares in the company, valued at approximately $8,133,999.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Board Co Advisory sold 1,936,529 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $22.50, for a total transaction of $43,571,902.50. Following the transaction, the insider now owns 4,445,879 shares in the company, valued at approximately $100,032,277.50. The disclosure for this sale can be found here. Corporate insiders own 8.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Issue Forecasts for Evolent Health Inc.’s Q2 2017 Earnings (EVH)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/23/analysts-issue-forecasts-for-evolent-health-inc-s-q2-2017-earnings-evh.html.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.